List of Bioinformatics Companies in Germany - 20

ALACRIS Theranostics GmbH is a Berlin-based systems medicine company founded in 2008, originating as a spin-off from the Max Planck Institute for Molecular Genetics. The company focuses on developing innovative solutions in healthcare, particularly in biomarker discovery, drug development, and precision medicine, with an emphasis on molecular oncology. The company offers comprehensive Next-Generation Sequencing (NGS) services that enhance precision medicine. By integrating advanced omics technologies with mechanistic computer modeling, ALACRIS develops biomarkers of drug response. Their services include high-dimensional data analytics and bioinformatics systems, tailored to meet medical needs in collaboration with clinicians. ALACRIS Theranostics is actively involved in partnerships with academia, biotechnology, and pharmaceutical companies, contributing to various research projects and applying their technologies in clinical settings. ALACRIS is committed to delivering data quickly while ensuring quality and confidentiality. Their interdisciplinary team combines expertise in sequencing technologies, advanced computing, and bioinformatics to provide effective healthcare solutions.

ATLAS Biolabs is a leading European service provider of complex analyses in molecular genetics including next-generation sequencing and microarray services supplemented by high-level data analysis. In addition to the high standard and quality, a key benefit of using ATLAS Biolabs’ service portfolio is the close relationship that we build to our customers during project planning and realization. Our quality management is organized according to ISO 9001:2015.

Axolabs specialises in a new class of drugs whose active ingredients are chemically derived from DNA or RNA. They are called oligonucleotide or nucleic acid therapeutics. We use our many years of expertise to help our clients make them a success. Some of these drugs have already been approved and are being used successfully against diseases that were previously untreatable in some cases. New drugs from this class are added every year. Axolabs is part of the LGC Group. Its business unit for nucleic acid therapeutics is combined under the brand name Axolabs. Axolabs operates companies in the following locations: Axolabs, Kulmbach, Germany Axolab Kulmbach GmbH, is the world's leading custom research organization in the field of nucleic acid therapeutics with a wide range of services. Axolabs Berlin, Berlin, Germany Axolabs Berlin is currently establishing a new site in Berlin for GMP manufacturing of nucleic acid therapeutics. The site will be dedicated to medium to large scale and early to late phase clinical GMP manufacturing of nucleic acid therapeutics. The state-of-the-art facility will deliver integrated analytical and manufacturing solutions. The operational start date is scheduled for 2024. Axolabs Petaluma, Petaluma, California, USA Axolabs operates a cGMP production facility in Petaluma for oligonucleotide compounds for technical, toxicological and preclinical to late-stage clinical trials. Services: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis.

bio.logis is a digital genomics company starting as a spin-off from a genetic diagnostic laboratory setting. Our goal is to develop smart applications and functionalities to drive the implementation of genetic data into clinical decision making. For laboratories and hospitals, we provide highly innovative software solutions enabling automated interpretation, diagnostic reporting & delivery of genetic data. This supports patients and physicians at point of care in making informed decisions based on information derived from DNA. Our vision We want DNA owners to have easy and secure access to reliable health-related information based on their DNA. Our goal is to create a sustainable ecosystem, where all stakeholders contribute to and benefit from maximizing diagnostic quality, improving patient care and promoting research. Our background The bio.logis team consists of experienced human geneticists, scientists and IT experts. Building software solutions for complex medical tasks requires excellent software development expertise and a deep understanding of medical decision making processes. Our team has been formed with exactly this in mind: uniquely combining comprehensive genetic diagnostics knowledge and IT development expertise.

Biomax Informatics is a bioinformatics company that specializes in laboratory informatics and data analysis for research and development in the life sciences.

BIOTYPE is an innovative German solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products & services for reliable analysis and interpretation of clinical biomarkers. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes IVD assays for clinical diagnostics and RUO assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD-compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-biomarker testing. MODAPLEX addresses the growing need to simplify and accelerate precision testing by reliably delivering actionable molecular information required for biomarker-guided care in precision medicine. The MODAPLEX consolidates multi-gene testing into one workflow with same-day results. BIOTYPE‘s quality management system is certified according to ISO 9001:2015 & ISO 13485:2016.

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Computomics was founded to bring the latest bioinformatics discoveries to industry application, facilitating global agricultural development.Crops: Parse large genomic data sets for plant breeders, deliver breeding recommendations, and provide molecular biology insight to reduce crop area requirements.Animal Health: Assemble and annotate genomic data from your species of interest, compare time-series data and visualize genomic variation in insightful ways.Metagenomics and Microbial Genomics: Analyze complex microbial communities and discover new organisms and metabolic pathways in a variety of samples.

DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.

MN-AM offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and R&D programs. Founded in 1997, the technology and knowhow of MN-AM is utilized worldwide in more than 150 major industrial, governmental and academic discovery laboratories as well as in regulatory agencies to design and optimize chemical products and to support the safety and risk assessment process. The product portfolio of MN-AM comprises a variety of software and database applications in the area of computational toxicology and chemoinformatics ranging from unique knowledgebases of expert QC'ed in vivo and in vitro toxicity information to in silico predictions of chemical, physical, biological and toxicological properties of chemical compounds including their reactivity and metabolic fate. Members of MN-AM share expertise in molecular informatics, chemometrics, computational modeling and analysis and statistical design of experiments. The MN-AM software development team has extensive experiences in systems development for internationally-funded projects, including private and public projects such as Seurat-1 COSMOS, IMI (eTOX, iPiE), IMI 2 (eTRANSAFE), and Horizon 2020 (ONTOX). MN-AM is also an experienced partner to develop custom-designed solutions suited to the partner's specific needs and has a unique expertise and technology to analyse and model proprietary chemical and biological data.

MSAID transforms the way scientists analyze proteomics data. MSAID is a bioinformatics spin-off from the Technical University of Munich, Germany and is located at the high-tech-center gate, which is part of the TUM campus in Garching. The company was founded by an interdisciplinary team of scientists with the vision to provide better computational solutions to the field of proteomics. The team has an exceptionally strong track record and long-standing expertise in the acquisition, analysis, and interpretation of proteomic data. Our ambition is to replace current algorithms for proteomics with powerful, AI-based solutions, thereby paving the way for a smarter, deeper, and more reliable way of interrogating proteomic data. Legal Notice: https://www.msaid.de/legal-notice

Noscendo GmbH, a Duisburg (Germany) based molecular diagnostics company, changes the way infection causative microbes are identified. Introducing a paradigm shift using proprietary algorithms and software harnessing next generation sequencing of cell free nucleic acids isolated from patient samples Noscendo brings the concept of liquid biopsy into the field of infectious diseases. Noscendo’ s software solution is capable of differentiating infection from non-infectious signals and thereby aiding intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.

Omiqa is a contract research organisation, specialising in providing efficient bioinformatics solutions to support life scientist. Our expertise spans from conducting cutting-edge research and developing large-scale bioinformatic workflows to creating custom graphical web and desktop applications.

No more data siloes. No more missed connections. Advanced chemical search and analysis made accessible to all. Unlock and extract insight for life sciences and chemistry. OntoChem enables your teams to consolidate and normalize all internal and external data from knowledge scattered across different documents, systems and geographical locations. OntoChem is part of Digital Science. Visit our website at ontochem.com

Developing therapeutics to elevate egg quality for IVF success.

ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms. Our deep history of analytical leadership in protein-based therapeutics stems from the merger of Protagen Protein Services in Europe and BioAnalytix in the US. In 2021, GeneWerk’s unique capabilities in vector safety, integration site analysis, and bioinformatics were added to our portfolio, establishing ProtaGene. Our combined protein- and gene-based analytical platforms make it the leading analytic service provider across the biopharmaceutical and gene and cell therapy development spaces. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide.

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout your project: Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. Technical Expertise: Our team provides unmatched proficiency in your proteomic analysis endeavors. Customized Solutions: We provide customized solutions to meet your specific research needs. Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report. Our Platform Is Used For: • Protein Biomarker Identification and Verification • Novel Drug Target Discovery • Mode-of-Action Analysis • Pathway Activity Analysis • Disease Model Characterization, among other key applications Join us on our mission to revolutionize medicine! #PrecisionMedicine #Proteomics

Unlocking tRNA modifications for drug development

We provide innovative gene editing reagents, screening services and engineered model systems for the global R&D market. Our success is based on the proprietary 3Cs technology.